JNJ vs BMY
By Alex · Tickerpine
Johnson & Johnson vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | BMY |
|---|---|---|
| Price | $285.75 | $63.43 |
| Market cap | $687.89B | $129.66B |
| P/E ratio | 43.4 | 14.1 |
| ROE | 20.02% | 44.01% |
| Profit margin | 16.20% | 18.47% |
| Revenue growth | 5.90% | 6.90% |
| Dividend yield | 1.88% | 3.97% |
| Beta | 0.20 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs BMY in plain English
- JNJ is the bigger company — about 5.3× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.1 vs 43.4).
- BMY earns a higher return on equity (44% vs 20%).
- BMY is growing revenue faster (7% vs 6%).
- BMY has the higher dividend yield (3.97% vs 1.88%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.